Monday, 31 August 2026European Markets

FAGRON Stock Bullish By 15% In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of FAGRON (BEL 20: FAGR.BR) jumped by a staggering 15.33% in 5 sessions from 13.18 € to 15.20 € at 01:13 EST on Monday, following the last session's upward trend. BEL 20 is falling 0.88% to 3,887.49 €, after two sequential sessions in a row of gains.

About FAGRON

Fagron NV, a pharmaceutical compounding company, provides personalized medicine care to hospitals, pharmacies, clinics, and patients. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. In addition, it supplies raw materials, utensils and equipment, semi-finished products, vehicles, and sterile and non-sterile compounded medicines. Further, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. It has operations in Latin America, North America, Europe, the Middle East, and Africa. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.

Earnings Per Share

As for profitability, FAGRON has a trailing twelve months EPS of 0.82 €.

PE Ratio

FAGRON has a trailing twelve months price to earnings ratio of 18.54. Meaning, the purchaser of the share is investing 18.54 € for every euro of annual earnings.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, FAGRON's stock is considered to be overbought (>=80).

More news about FAGRON (FAGR.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com